Literature DB >> 8891252

Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain.

K Matsuura1, H Kabuto, H Makino, N Ogawa.   

Abstract

To reveal new therapeutic strategies for Parkinson's disease (PD), we investigated the protective effect of an immunosuppressant, cyclosporin A (CsA), against 6-hydroxydopamine (6-OHDA)-induced injury of nigrostriatal dopamine neurons in mice. Seven days after induction of 6-OHDA lesion, dopamine (DA) and homovanillic acid (HVA) in the striatum were depleted by 60 and 50%, respectively, and repeated high dose CsA (20 mg/kg) treatment significantly protected against these depletions. HVA and dihydroxyphenylacetic acid (DOPAC) in the substantia nigra were depleted by 40%, and CsA significantly increased HVA and DOPAC in 6-OHDA-lesioned mice. Furthermore, CsA increased the [DOPAC + HVA]/DA ratio in the substantia nigra, indicating that DA metabolism was stimulated by CsA in 6-OHDA-lesioned mice. These results suggest that CsA is beneficial in reducing 6-OHDA-induced injury of nigrostriatal DA neurons, indicating the therapeutic potential of immunosuppressants in PD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891252     DOI: 10.1016/0006-8993(96)00686-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Differential involvement of mitochondrial permeability transition in cytotoxicity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine.

Authors:  Chung Soo Lee; Woo Jae Park; Hyun Hee Ko; Eun Sook Han
Journal:  Mol Cell Biochem       Date:  2006-04-20       Impact factor: 3.396

Review 2.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

3.  Immunophyllin ligands show differential effects on alcohol self-administration in C57BL mice.

Authors:  Thomas Beresford; Tina Fay; Natalie J Serkova; Peter H Wu
Journal:  J Pharmacol Exp Ther       Date:  2012-02-28       Impact factor: 4.030

4.  FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

Authors:  S Hunot; N Dugas; B Faucheux; A Hartmann; M Tardieu; P Debré; Y Agid; B Dugas; E C Hirsch
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

Review 5.  FK506 and the role of immunophilins in nerve regeneration.

Authors:  B G Gold
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

6.  Proteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease.

Authors:  Jae Ho Kim; Julien Franck; Taewook Kang; Helmut Heinsen; Rivka Ravid; Isidro Ferrer; Mi Hee Cheon; Joo-Yong Lee; Jong Shin Yoo; Harry W Steinbusch; Michel Salzet; Isabelle Fournier; Young Mok Park
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

7.  Loss of DJ-1 does not affect mitochondrial respiration but increases ROS production and mitochondrial permeability transition pore opening.

Authors:  Emilie Giaime; Hiroo Yamaguchi; Clement A Gautier; Tohru Kitada; Jie Shen
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

8.  Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.

Authors:  Anna Tamburrino; Madeline J Churchill; Oi W Wan; Yolanda Colino-Sanguino; Rossana Ippolito; Sofie Bergstrand; Daniel A Wolf; Niculin J Herz; Michelle D Sconce; Anders Björklund; Charles K Meshul; Mickael Decressac
Journal:  Acta Neuropathol Commun       Date:  2015-12-14       Impact factor: 7.801

9.  Effects of Tacrolimus and Other Immune Targeting Compounds on Binge-Like Ethanol Drinking in High Drinking in the Dark Mice.

Authors:  Kolter B Grigsby; Antonia M Savarese; Pamela Metten; Barbara J Mason; Yuri A Blednov; John C Crabbe; Angela R Ozburn
Journal:  Neurosci Insights       Date:  2020-11-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.